An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Acadia Pharmaceuticals (Nasdaq: ACAD) will announce its first quarter financial results on May 8, 2024. The company will host a conference call and webcast to discuss financial results and operations. The call will be available on Acadia's website and archived until June 7, 2024.
Acadia Pharmaceuticals (Nasdaq: ACAD) annuncerà i suoi risultati finanziari del primo trimestre l'8 maggio 2024. L'azienda ospiterà una conferenza telefonica e un webcast per discutere dei risultati finanziari e delle operazioni. La chiamata sarà disponibile sul sito web di Acadia e archiviata fino al 7 giugno 2024.
Acadia Pharmaceuticals (Nasdaq: ACAD) anunciará sus resultados financieros del primer trimestre el 8 de mayo de 2024. La compañía organizará una llamada de conferencia y una transmisión web para discutir los resultados financieros y las operaciones. La llamada estará disponible en el sitio web de Acadia y archivada hasta el 7 de junio de 2024.
아카디아 파마슈티컬스 (나스닥: ACAD)는 2024년 5월 8일에 첫 번째 분기 재무 결과를 발표할 예정입니다. 회사는 재무 결과와 운영에 대해 논의하기 위해 전화 회의 및 웹캐스트를 주최할 것입니다. 전화 회의는 아카디아 웹사이트에서 사용할 수 있으며 2024년 6월 7일까지 보관됩니다.
Acadia Pharmaceuticals (Nasdaq: ACAD) annoncera ses résultats financiers du premier trimestre le 8 mai 2024. La société organisera une conférence téléphonique et un webcast pour discuter des résultats financiers et des opérations. L'appel sera disponible sur le site web d'Acadia et archivé jusqu'au 7 juin 2024.
Acadia Pharmaceuticals (Nasdaq: ACAD) wird seine Finanzergebnisse für das erste Quartal am 8. Mai 2024 bekannt geben. Das Unternehmen wird eine Telefonkonferenz und einen Webcast veranstalten, um die Finanzergebnisse und Geschäftsvorgänge zu diskutieren. Der Anruf wird auf der Website von Acadia verfügbar sein und bis zum 7. Juni 2024 archiviert.
Positive
None.
Negative
None.
Company to host conference call and webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
The conference call will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until June 7, 2024. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
